Jürgen Krauss

Summary

Affiliation: University of Essen
Country: Germany

Publications

  1. ncbi request reprint Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein
    Jürgen Krauss
    Department of Medical Oncology and Cancer Research, University of Essen, D 45122 Essen, Germany
    Biochem Biophys Res Commun 331:595-602. 2005
  2. ncbi request reprint Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme
    Jürgen Krauss
    SAIC, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Br J Haematol 128:602-9. 2005
  3. ncbi request reprint Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment
    Jürgen Krauss
    National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Protein Eng 16:753-9. 2003
  4. ncbi request reprint A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells
    Michaela A E Arndt
    University of Essen, Institute of Immunology, 45122 Essen, Germany
    J Immunother 28:245-51. 2005
  5. ncbi request reprint Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma
    Michaela A E Arndt
    National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Int J Cancer 107:822-9. 2003
  6. ncbi request reprint Bispecific diabodies for cancer therapy
    Michaela Arndt
    National Cancer Institute at Frederick, Frederick, MD, USA
    Methods Mol Biol 207:305-21. 2003
  7. ncbi request reprint Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers
    Michaela A E Arndt
    SAIC, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    FEBS Lett 578:257-61. 2004
  8. ncbi request reprint Chimerization of a monoclonal antibody for treating Hodgkin's lymphoma
    Jürgen Krauss
    National Cancer Institute at Frederick, Frederick, MD, USA
    Methods Mol Biol 207:63-79. 2003
  9. ncbi request reprint Application of recombinant antibodies in cancer patients
    Jürgen Krauss
    National Cancer Institute at Frederick, Frederick, MD, USA
    Methods Mol Biol 207:27-53. 2003
  10. ncbi request reprint Recombinant antibodies for the diagnosis and treatment of cancer
    Jürgen Krauss
    SAIC Frederick, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Mol Biotechnol 25:1-17. 2003

Detail Information

Publications10

  1. ncbi request reprint Efficient killing of CD22+ tumor cells by a humanized diabody-RNase fusion protein
    Jürgen Krauss
    Department of Medical Oncology and Cancer Research, University of Essen, D 45122 Essen, Germany
    Biochem Biophys Res Commun 331:595-602. 2005
    ..Our results demonstrate that engineering of dimeric antibody-ribonuclease fusion proteins can markedly enhance their biological efficacy...
  2. ncbi request reprint Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme
    Jürgen Krauss
    SAIC, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Br J Haematol 128:602-9. 2005
    ....
  3. ncbi request reprint Specificity grafting of human antibody frameworks selected from a phage display library: generation of a highly stable humanized anti-CD22 single-chain Fv fragment
    Jürgen Krauss
    National Cancer Institute at Frederick, Frederick, MD 21702, USA
    Protein Eng 16:753-9. 2003
    ..We expect this approach may be applicable for the rapid generation of highly stable humanized antibodies with low immunogenic potential...
  4. ncbi request reprint A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells
    Michaela A E Arndt
    University of Essen, Institute of Immunology, 45122 Essen, Germany
    J Immunother 28:245-51. 2005
    ..These results show that the therapeutic potential of scFv-ANG fusion proteins can be markedly enhanced by engineering dimeric derivatives...
  5. ncbi request reprint Generation of a highly stable, internalizing anti-CD22 single-chain Fv fragment for targeting non-Hodgkin's lymphoma
    Michaela A E Arndt
    National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Int J Cancer 107:822-9. 2003
    ..These properties predict scFv MJ-7 could become a novel powerful tool to selectively deliver cytotoxic agents to malignant CD22+ cells...
  6. ncbi request reprint Bispecific diabodies for cancer therapy
    Michaela Arndt
    National Cancer Institute at Frederick, Frederick, MD, USA
    Methods Mol Biol 207:305-21. 2003
  7. ncbi request reprint Antigen binding and stability properties of non-covalently linked anti-CD22 single-chain Fv dimers
    Michaela A E Arndt
    SAIC, National Cancer Institute at Frederick, Frederick, MD 21702, USA
    FEBS Lett 578:257-61. 2004
    ..These properties suggest the V(L)-0-V(H) scFv could become an attractive vehicle for the selective delivery of multiple effector molecules to CD22(+) tumor cells...
  8. ncbi request reprint Chimerization of a monoclonal antibody for treating Hodgkin's lymphoma
    Jürgen Krauss
    National Cancer Institute at Frederick, Frederick, MD, USA
    Methods Mol Biol 207:63-79. 2003
  9. ncbi request reprint Application of recombinant antibodies in cancer patients
    Jürgen Krauss
    National Cancer Institute at Frederick, Frederick, MD, USA
    Methods Mol Biol 207:27-53. 2003
  10. ncbi request reprint Recombinant antibodies for the diagnosis and treatment of cancer
    Jürgen Krauss
    SAIC Frederick, National Cancer Institute at Frederick, Frederick, MD 21702 1201, USA
    Mol Biotechnol 25:1-17. 2003
    ..It also discusses clinically relevant aspects of the use of recombinant antibodies in cancer patients...